Heart Failure Clinical Trial
Official title:
An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients With Cardiorenal Syndrome
NCT number | NCT04145635 |
Other study ID # | PVP017 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 5, 2021 |
Est. completion date | March 9, 2023 |
Verified date | April 2024 |
Source | Procyrion |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Aortix CRS Pilot Study: An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome
Status | Completed |
Enrollment | 21 |
Est. completion date | March 9, 2023 |
Est. primary completion date | October 7, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1) Admitted to the hospital with a primary diagnosis of acute decompensated heart failure, either heart failure with reduced or preserved ejection fraction (HFrEF, HFpEF or HFmEF); 2) Worsening renal function (serum creatinine increase by =0.3 mg/dl [=27 µmol/L]) despite 48 hours of intravenous diuretic therapy Increase can be compared to a baseline value taken within 90 days of hospitalization or during hospitalization; 3) Objective measure of congestion (Elevated PCWP [=20 mmHg] OR Elevated CVP [=12 mmHg]) obtained via catheter measurement; 4) Persistent clinical signs and/or symptoms of congestion despite diuretic therapy (one or more of the following): 1. dyspnea at rest or with minimal exertion, 2. paroxysmal nocturnal dyspnea, 3. orthopnea, 4. lower extremity edema (=2+), 5. elevated jugular venous pressure, 6. pulmonary rales, 7. enlarged liver or ascites, 8. pulmonary vascular congestion on chest x-ray; 5) Age >21 years. - Exclusion Criteria: 1) Treatment with high dose IV inotropes within the last 48 hours. High dose is defined as > 1 unit of inotrope (excluding digoxin) as follows: 5 µg/kg/min dopamine = 1 unit, 5 µg/kg/min dobutamine= 1 unit, 0.375 µg/kg/min milrinone = 1 unit, (for example, dopamine 2.5 µg/kg/min + dobutamine 2.5 µg/kg/min = 1 unit; dobutamine 2.5 µg/kg/min + milrinone 0.1875 µg/kg/min = 1 unit); 2) Treatment with vasopressors to maintain blood pressure as per exclusion number 3; 3) Active and ongoing hypotension defined as a systolic blood pressure < 90 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) < 60 mmHg lasting more than 30 minutes; 4) Acute Kidney Failure defined as increase in serum creatinine to =4.0 mg/dL (=353.6 µmol/L) within the last 48 hours; 5) Exposure to intravenous contrast, aminoglycosides or high dose NSAIDS in the 48 hours before enrollment; 6) Known or suspected contrast induced nephropathy; 7) Prior kidney transplant, isolated single kidney, stage V Chronic Kidney Disease (eGFR =15) at admission OR use of dialysis, continuous renal replacement therapy (CRRT) or aquapheresis (ultrafiltration) in last 90 days; 8) Urologic intervention (except indwelling urinary (Foley) catheter)) within the last 7 days; 9) Known cirrhosis or shock liver; 10) Presence of an active infection; 11) Prior heart transplant in the last 2 years, heart failure due to rejection of a previous heart transplant, planned heart transplantation before the 30-day follow-up visit; 12) Current or previous support with a durable LVAD at any time or use of an intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g. Impella or TandemHeart) currently or within the last 30 days; 13) Patient has known hypo- or hyper coaguable state such as disseminated intravascular coagulation or heparin induced thrombocytopenia (HIT); 14) Known cardiac amyloidosis; 15) Acute myocardial infarction Type 1 within 30 days of enrollment, or planned coronary revascularization; 16) Stroke within 30 days of enrollment; 17) Severe Bleeding Risk (any of the following): a) Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 7 days, b) GI bleeding within 6 months requiring hospitalization and/or transfusion, c) Recent major surgery within 6 months if the surgical wound is judged to be associated with an increased risk of bleeding, d) Endovascular procedure with ilio-femoral access > 6 FR within 30 days, e) Platelet count <75,000 cells/mm3, f) Uncorrectable bleeding diathesis or coagulopathy (e.g. INR =2 not due to anticoagulation therapy); 18) Current endovascular stent graft in the descending aorta or any femoro-iliac vessels; 19) Contraindicated Anatomy: 1. Descending aortic anatomy that would prevent safe placement of the device [<18mm or >31mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)], 2. Abnormalities of the aorta or iliac arteries that would prevent safe device placement, including aneurysms, significant tortuosity, or calcifications, 3. Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21F (outer diameter) introducer sheath including severe obstructive calcification or severe tortuosity, 4. Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury; 20) Known hypersensitivity or contraindication to study or procedure medications (e.g. anticoagulation therapy) or device materials (e.g. history of severe reaction to nickel or nitinol); 21) Positive pregnancy test if of childbearing potential; 22) Participation in any other clinical investigation that is likely to confound study results or affect the study; 23) Unable or unwilling to undergo screening (imaging, PA Catheter placement), device implant and retrieval procedures. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Prince Charles Hospital | Brisbane | Queensland |
Australia | The Alfred Hospital | Melbourne | Victoria |
Australia | Western Health, Footscray Hospital | Melbourne | Victoria |
Australia | St. Vincent's Hospital | Sydney | New South Wales |
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Chicago | Chicago | Illinois |
United States | Christ Hospital | Cincinnati | Ohio |
United States | University of Colorado | Denver | Colorado |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Inova Health Care Services | Falls Church | Virginia |
United States | University of Florida | Gainesville | Florida |
United States | Houston Methodist | Houston | Texas |
United States | University of Southern California | Los Angeles | California |
United States | Columbia University/New York Presbyterian | New York | New York |
United States | Sentara Hospital | Norfolk | Virginia |
United States | University of California, San Francisco | San Francisco | California |
United States | University of South Florida | Tampa | Florida |
United States | Cleveland Clinic Florida | Weston | Florida |
Lead Sponsor | Collaborator |
---|---|
Procyrion | Procyrion Australia Pty Ltd |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serious Adverse Events | Rate of Occurrence of Serious Adverse Events (rate will be calculated and reported) | 30 days | |
Primary | Serious Procedure Related Adverse Events | Rate of Occurrence of Serious Procedure Related Adverse Events (rate will be calculated and reported) | 30 days | |
Primary | Device Performance | Deployment and retrieval procedures success rates (rates will be calculated and reported). | 7 days | |
Primary | Device Performance | Rate of occurrence of ADS, ARS and pump device-related adverse events (includes device malfunctions) (rate will be calculated and reported) | 30 days | |
Primary | Effectiveness | Clinically significant decongestion as measured by the PA catheter. % of patients with a decrease in either CVP or PCWP of > 20%. | 7 days | |
Primary | Urine Output | Change in Urine Output Assessed as the hourly rate of urine output before pump placed vs hourly rate of urine output over the Aortix therapy period (until congestion target met or therapy deemed ineffective) | 7 day period starting from implant | |
Primary | NT-pro-BNP (Brain Natriuretic Peptide) | Change in NT-pro-BNP (pre-implant vs when congestion target is met or therapy deemed ineffective) | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|